Payment overview · 2025
General Payments
$226.26
13 reported records · 10 companies
Healthcare provider profile · identity verified
Bridgette Marie Baker, MD
Allopathic & Osteopathic Physicians|Family Medicine · BOISE, ID · NPI 1265693386
Verified facts
What the public records show
CMS Open Payments records show Bridgette Marie Baker, MD received $226.26 in general payments during 2025 across 13 reported records.
Astellas Pharma US Inc accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $45.73 | 20.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.61 | 16.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.11 | 16.0% | 2 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $17.80 | 7.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.22 | 7.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.26 | 7.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.26 | 7.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.43 | 6.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.71 | 6.1% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $11.13 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $226.26 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $45.73 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.61 | 2 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $36.61 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.61 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.11 | 2 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| LILETTA Normalized: liletta |
Drug | ABBVIE INC. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $11.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 127 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 118 | 45 |
| Lisinopril | Lisinopril | 104 | 34 |
| Omeprazole | Omeprazole | 70 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 26 |
| Gabapentin | Gabapentin | 68 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 18 |
| Losartan Potassium | Losartan Potassium | 67 | 32 |
| Sertraline Hcl | Sertraline Hcl | 64 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 62 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 14 |
| Metformin Hcl | Metformin Hcl | 53 | 25 |
| Potassium Chloride | Potassium Chloride | 49 | 16 |
| Trazodone Hcl | Trazodone Hcl | 49 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 11 |
| Carbamazepine | Carbamazepine | 34 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | 15 |
| Olanzapine | Olanzapine | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Simvastatin | Simvastatin | 30 | 11 |
| Eliquis | Apixaban | 28 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Furosemide | Furosemide | 26 | 11 |
| Meloxicam | Meloxicam | 26 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 15 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $226.26 · 13 records | Astellas Pharma US Inc | ABRYSVO, BREZTRI, COMIRNATY, Korlym, LILETTA, MOUNJARO, Ozempic, PENBRAYA, PREVNAR 20, Rybelsus, SLYND, SX-ONE MICROKNIFE, TRUMENBA, VOQUEZNA, Veozah, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rybelsus play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error